Miriam Monge to Join Sartorius Stedim Biotech as Director of Marketing for Integrated Solutions
Sartorius Stedim Biotech (SSB), has appointed Miriam Monge as Director of Marketing for SSB’s Integrated Solutions unit. In this newly created position, Monge will focus on sharpening SSB’s profile as an integrated solution provider for the biopharmaceutical industry.
Miriam Monge brings in more than 20 years of experience in the biopharmaceutical manufacturing sector and served, most recently, as Vice President of Sales & Marketing at the consultancy Biopharm Services. She is a committee member of the International Society for Pharmaceutical Engineering (ISPE) and one of the founders of the Global Disposable Community of Practice. Miriam Monge regularly authors articles for technical bioprocess journals, analysing the impact of disposable technologies on biomanufacturing.
“With Miriam Monge, we have gained an internationally recognised expert from the biopharmaceutical industry who will help us further position Sartorius Stedim Biotech as a total solution provider for biopharma companies, “ stated Reinhard Vogt, member of the SSB Board of Directors. “Whenever our customers start planning a new facility or process, SSB’s Integrated Solutions unit is an ideal partner for designing and implementing entire single-use or hybrid production processes.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...